All Stories

  1. Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system

    Article • PLoS ONE, December 2019, PLOS

    Dr Raymond K Cross

  2. Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease

    Article • Expert Opinion on Investigational Drugs, March 2019, Taylor & Francis

    Dr Raymond K Cross

  3. Adverse events in IBD therapy: the 2018 update

    Article • Expert Review of Gastroenterology & Hepatology, November 2018, Taylor & Francis

    Dr Raymond K Cross

  4. Exercise in patients with inflammatory bowel diseases: current perspectives

    Article • Clinical and Experimental Gastroenterology, December 2017, Dove Medical Press

    Dr Raymond K Cross

  5. Medical versus surgical management of penetrating Crohn’s disease: the current situation and future perspectives

    Article • Expert Review of Gastroenterology & Hepatology, June 2017, Taylor & Francis

    Dr Raymond K Cross

  6. Cigarette smoking adversely affects disease activity and disease-specific quality of life in patients with Crohn’s disease at a tertiary referral center

    Article • Clinical and Experimental Gastroenterology, September 2016, Dove Medical Press

    Dr Raymond K Cross

  7. Differential response to microbial antigens by age of diagnosis in patients with Crohn's disease

    Article • Clinical and Experimental Gastroenterology, June 2015, Dove Medical Press

    Dr Raymond K Cross, Mr Guruprasad D Jambaulikar

  8. The role of telemedicine and e-health in the management of inflammatory bowel disease: improving patient outcomes

    Article • Smart Homecare Technology and TeleHealth, January 2015, Taylor & Francis

    Dr Raymond K Cross